drugset / Trial / NCT05187429
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This is the reason why people living with HIV are unable to stop their antiretroviral treatment.
Timeline
- Start
- 2023-01-24
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | Intravenous |